 BridgeBio Pharma Inc NASDAQ: BBIO announced promising pharmacodynamic data from the first two participants dosed in CANaspire Phase 12 trial of BBP-812, gene therapy for Canavan disease. Canavan disease is an ultra-rare inherited disorder that damages the ability of nerve. 